国外医学（医学地理分册）
國外醫學（醫學地理分冊）
국외의학（의학지리분책）
FOREIGN MEDICAL SCIENCES(SECTION OF MEDGEOGRAPHY)
2014年
3期
227-229,238
,共4页
白玉云%赵子霞%魏玮%李晨刚
白玉雲%趙子霞%魏瑋%李晨剛
백옥운%조자하%위위%리신강
2 型糖尿病%高脂血症%高敏C反应蛋白%瑞舒伐他汀%红细胞分布宽度
2 型糖尿病%高脂血癥%高敏C反應蛋白%瑞舒伐他汀%紅細胞分佈寬度
2 형당뇨병%고지혈증%고민C반응단백%서서벌타정%홍세포분포관도
type 2 diabetes mellitus%hyperlipemia%C-reactive protein%rosuvastatin red blood cell distribution width
目的：探讨非高脂血症2型糖尿病患者血清高敏 C 反应蛋白(hs-CRP)和红细胞分布宽度(RDW)的变化及瑞舒伐他汀对其影响。方法138例非高脂血症2型糖尿病患者随机分为瑞舒伐他汀治疗组和常规治疗组。瑞舒伐他汀组在常规治疗的基础上加瑞舒伐他汀10 mg,1次/晚。分别测定治疗前及治疗1、3和6月后血清 hs-CRP 和RDW,以60例健康人为对照。结果血脂不高的2型糖尿病患者,血浆 hs-CRP浓度明显高于正常人[(4.13±1.12) mg/L vs.(2.36±1.37)mg/L,P<0.05]；RDW也显著高于正常人[(13.9±1.2)% vs.(12.7±0.9)%,P<0.05]；瑞舒伐他汀治疗1月后 hs-CRP显著降低[(4.13±1.23)mg/L vs.(3.12±1.36)mg/L,P<0.05],3个月后RDW也显著降低[(13.8±1.4)%vs.(13.0±1.5)%,P<0.05],常规治疗组6个月观察期内 hs-CRP和 RDW无明显变化。结论血脂不高的2型糖尿病患者也存在着慢性炎症反应和 RDW升高,瑞舒伐他汀治疗降低了血脂不高的2型糖尿病患者的炎症反应,同时也显著降低了 RDW。
目的：探討非高脂血癥2型糖尿病患者血清高敏 C 反應蛋白(hs-CRP)和紅細胞分佈寬度(RDW)的變化及瑞舒伐他汀對其影響。方法138例非高脂血癥2型糖尿病患者隨機分為瑞舒伐他汀治療組和常規治療組。瑞舒伐他汀組在常規治療的基礎上加瑞舒伐他汀10 mg,1次/晚。分彆測定治療前及治療1、3和6月後血清 hs-CRP 和RDW,以60例健康人為對照。結果血脂不高的2型糖尿病患者,血漿 hs-CRP濃度明顯高于正常人[(4.13±1.12) mg/L vs.(2.36±1.37)mg/L,P<0.05]；RDW也顯著高于正常人[(13.9±1.2)% vs.(12.7±0.9)%,P<0.05]；瑞舒伐他汀治療1月後 hs-CRP顯著降低[(4.13±1.23)mg/L vs.(3.12±1.36)mg/L,P<0.05],3箇月後RDW也顯著降低[(13.8±1.4)%vs.(13.0±1.5)%,P<0.05],常規治療組6箇月觀察期內 hs-CRP和 RDW無明顯變化。結論血脂不高的2型糖尿病患者也存在著慢性炎癥反應和 RDW升高,瑞舒伐他汀治療降低瞭血脂不高的2型糖尿病患者的炎癥反應,同時也顯著降低瞭 RDW。
목적：탐토비고지혈증2형당뇨병환자혈청고민 C 반응단백(hs-CRP)화홍세포분포관도(RDW)적변화급서서벌타정대기영향。방법138례비고지혈증2형당뇨병환자수궤분위서서벌타정치료조화상규치료조。서서벌타정조재상규치료적기출상가서서벌타정10 mg,1차/만。분별측정치료전급치료1、3화6월후혈청 hs-CRP 화RDW,이60례건강인위대조。결과혈지불고적2형당뇨병환자,혈장 hs-CRP농도명현고우정상인[(4.13±1.12) mg/L vs.(2.36±1.37)mg/L,P<0.05]；RDW야현저고우정상인[(13.9±1.2)% vs.(12.7±0.9)%,P<0.05]；서서벌타정치료1월후 hs-CRP현저강저[(4.13±1.23)mg/L vs.(3.12±1.36)mg/L,P<0.05],3개월후RDW야현저강저[(13.8±1.4)%vs.(13.0±1.5)%,P<0.05],상규치료조6개월관찰기내 hs-CRP화 RDW무명현변화。결론혈지불고적2형당뇨병환자야존재착만성염증반응화 RDW승고,서서벌타정치료강저료혈지불고적2형당뇨병환자적염증반응,동시야현저강저료 RDW。
Objective The aim of this study was to investigate the change of serum high sensitive C-reactive protein(hs-CRP)and red blood cell distribution width(RDW)in patients with no hyperlipemia type 2 diabetes melli-tus and the effect of rosuvastatin on the change.Methods 138 patients with no hyperlipemia type 2 diabetes melli-tus were randomly assigned into conventional treatment group and rosuvastatin treatment group,The rosuvastatin treatment group were given 10mg simvastatin nightly in addition to conventional treatment.The serum hs-CRP and RDW were measured before and after 1,3 and 6 months treatment,and compared with that in 60 healthy subjects. Results The level of hs-CRP in patients with no hyperlipemia type 2 diabetes mellitus was significantly higher than that of normal control [(4.13±1.12)mg/L vs.(2.36±1.37)mg/L,P<0.05]and RDW was also significantly higher than that of normal control[(13.9±1.2)% vs.(12.7±0.9)%,P<0.05].In the rosuvastatin treatment group,the hs-CRP concentration was significantly decreased[(4.13±1.23)mg/L vs.(3.12±1.36)mg/L,P<0.05]after 1 month of treatment and the RDW was also significantly decreased[(13.8±1.4)% vs.(13.0±1.5)%, P<0.05]after 3 months of treatment with rosuvastatin.In the conventional treatment group,the hs-CRP and RDW didn’t significantly change in a period of 6 months’following-up.Conclusion Chronic inflammation and the increasment of RDW are present in patients with no hyperlipemia type 2 diabetes mellitus.Rosuvastatin significantly reduces the inflammation and alsodecrease RDW.
